A viral strategy to ambush tumors.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 21738155.
- Also identified by DOI 10.1038/nm0711-784 and PMC identifier 4256679.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A new combinatorial approach harnesses the power of immuno- and virotherapy in a vesicular stomatitis virus (VSV) vector carrying a cDNA library that expresses normal human prostate antigens, thus providing proof of principle that this vaccine can induce prostate tumor rejection in mice (pages 854–859). This strategy might bypass many of the issues associated with conventional cancer immuno- or virotherapy.
Medical subject headings
- Antigens, Neoplasm
- Cancer Vaccines
- Prostatic Neoplasms